Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Delavirdine mesylate
Drug ID BADD_D00604
Description A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Indications and Usage For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
Marketing Status approved
ATC Code J05AG02
DrugBank ID DB00705
KEGG ID D00895
MeSH ID D020008
PubChem ID 441386
TTD Drug ID D0G6SD
NDC Product Code Not Available
UNII 421105KRQE
Synonyms Delavirdine | Rescriptor | U-90152 | U 90152 | U90152 | U-90152S | U 90152S | U90152S | Delavirdine Mesylate | Mesylate, Delavirdine
Chemical Information
Molecular Formula C23H32N6O6S2
CAS Registry Number 147221-93-0
SMILES CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tooth abscess07.09.01.003; 11.01.04.003---
Toothache07.09.06.001--
Tremor17.01.06.002--
Tuberculosis11.04.01.006---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001---
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Fat redistribution14.08.04.002---
Localised oedema02.05.04.006; 08.01.07.011; 14.05.06.009--
Contusion12.01.06.001; 15.03.05.007; 23.03.11.002; 24.07.06.001--
Respiratory tract congestion22.02.07.003---
Affect lability19.04.01.001---
Body fat disorder14.08.04.012---
Cognitive disorder17.03.03.003; 19.21.02.001--
Nuchal rigidity15.05.04.005; 17.05.02.006---
Blood alkaline phosphatase increased13.04.02.004--
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Skin mass23.07.04.014---
Acute kidney injury20.01.03.016--
Anal incontinence07.01.06.029; 17.05.01.021--
Intermenstrual bleeding21.01.01.015---
The 7th Page    First    Pre   7    Total 7 Pages